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Follow-up program in squamous cell carcinoma of head and neck district is crucial to detect locoregional recurrence and second
primary tumors and to manage treatment toxicities. The choice of the appropriate frequency of visits and imaging modality can be
troublesome. Details of timing surveillance and type of diagnostic procedure are still not well defined. This review highlights the
problem from a clinician’s point of view.
1. Introduction
A review of recent developments of follow-up management
for head and neck (H&N) cancer is presented. Considering
the multiple site and histological classification of H&N can-
cer, we focus on nasopharynx and squamous cell carcinoma,
which includes primary sites in oral cavity, hypopharynx,
oropharynx, and larynx. Although the prognosis of H&N
cancer depends on primary tumor site, the posttreatment
evaluation is common in all H&N district.
The design of follow-up program is a relatively recent
research area. In the past few years the concept of conser-
vative treatments became the primary end-point. The appro-
priate management has been driven not only by innovations
in the delivery of medical care, but also by developments
in technology tools [1, 2]. On the other hand, posttreatment
follow-up gains importance in clinical performance. Optimal
form of surveillance is not clear and data regarding cost-
effectiveness of rigorous surveillance are lacking [3]. Despite
the timing protocol and the modalities used varying consid-
erably among clinicians, the aim of a prompt detection and
treatment of recurrent disease, as well as second primaries,
is a common denominator. Nowadays, follow-up should be
performed by a multiprofessional team, with expertise in
management and prevention of treatment toxicities. Current
modalities for follow-up include complete H&N clinical
exam and structural examinations.
2. Evidence of Follow-Up
Treatment failure in H&N cancer after surgery and/or
(chemo)radiotherapy is primarily associated with locore-
gional recurrence disease. Therefore posttreatment surveil-
lance should be focused on detecting tumor recurrence at an
early stage in order to provide a salvage procedure [4, 5].
2.1. Recurrent Tumor. Cancer recurrence is defined as the
reemerge of disease after treatment and after a 6-month
period of complete regression [6]. In H&N cancer, local
recurrence data vary from <10% to about 50%, based on
primary site and stage [7–10]. Surveillance programs are
based on the conventional assumption that early recurrence
detection is related to an increased survival. Actually, benefit
in cancer survival with routine surveillance has not been
well proven in literature. Most studies concluded that regular
follow-up does not influence survival outcomes [8, 9, 11–13].
With careful follow-up, recurrence could be detected, but
there is no evidence to support a real improvement in sur-
vival, in the physician-detected recurrent disease versus
patient-detected [13, 14]. Only one retrospective analysis [9]
resulted in better survival rates in detection of recurrence
with physical examination in comparison with the self-
referral recurrence (58 months versus 32 months, resp.; 𝑃
value < 0.05). This analysis is discordant with other studies
reported in literature. Flynn et al. [14] have shown that
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Table 1: Guidelines for follow-up intervals for head and neck cancers.
NCCN AIRO BAHNO
Clinical exam Imaging Clinical exam Imaging Clinical exam Imaging
Year 1 Every 1–3mo Within 6mo Every 1-2mo Every 6mo Every 4–6we Within 3mo
Year 2 Every 2–6mo — Every 2-3mo Every 6mo Every 4–6we —
Year 3 Every 4–8mo — Every 4–6mo —∗ Every 3mo —
Year 4 Every 4–8mo — Every 4–6mo —∗ Every 6mo —
Year 5 Every 4–8mo — Every 4–6mo — Every 6mo —
>5 years Every 12mo — Every 6–12mo — Every 12mo —
∗If nasopharynx, RM every 6 months for 4 years.
NCCN: National Comprehensive Cancer Network; AIRO: Associazione Italiana Radioterapia Oncologica; BAHNO: British Association of Head and Neck
Oncologists; mo: month; we: week.
an adequate follow-up frequency is important to evaluate
treatment results, to manage late complication, and to offer
emotional support. They conducted a retrospective analysis
of 223 patients with advanced H&N cancer treated with
curative intent. In early physician detection of locoregional
recurrence, no improvement in survival was demonstrated.
Because most recurrences are reported by the patient,
a training to recognise symptoms or signs should be
paramount. Increased local pain, development of a new lump
in the neck, unexplained weight loss, and increased difficulty
in swallowing suggest recurrence. Most recurrences appear
within 18 months, but late recurrences may appear after 5
years, especially for laryngeal primaries [7].
2.2. Second Primary Tumour. Patients with previous H&N
malignancy run a high risk (10–20%) of developing second
primary cancer in lung or upper aerodigestive tract, due to
the same risk factors, chronic nicotine and alcohol intake.
Although this evidence is well documented in literature, the
impact of early detection on survival is not clear, considering
their poor prognosis [15–17].
3. Head and Neck Cancer
Surveillance Protocols
Follow-up of patients with H&N cancer, firstly, should focus
on early detection of locoregional recurrence and manage-
ment of adverse symptoms or posttreatment complications.
Appropriate follow-up program should be performed accord-
ing to guidelines. At present several guidelines are available,
but there is insufficient evidence to recommend one guideline
to others. Table 1 summarizes the main schedules of follow-
up in literature.
3.1. National Comprehensive Cancer Network. The National
Comprehensive Cancer Network (NCCN) guidelines recom-
mend complete clinical exam, including fiberoptic examina-
tion, every 1 to 3months for the first year, every 2 to 6months
for the second year, every 4 to 8 months for the third to
fifth years, and annually thereafter. A posttreatment baseline
imaging exam within 6 months of RT/CRT treatment is
recommended for T3-4 or N2-3 cancer of the oropharynx,
hypopharynx, glottic and supraglottic larynx, and nasophar-
ynx only. The NCCN guidelines believe that it is safe and
reasonable to perform further imaging investigation based on
symptoms or signs. Patients with smoking history should be
monitored by chest imaging [18].
3.2. European Society for Medical Oncology. Recommen-
dation for H&N cancers’ surveillance is also provided by
European Society for Medical Oncology (ESMO) Guidelines
Working Group. Clinical and imaging exams should be
included to evaluate treatment response, but timing is not
specified. It is possible to deduce that imaging exams should
be performed in case of clinical suspicion of recurrence. A
posttreatment baseline imaging exam of primary localization
and neck is recommended [19].
3.3. Associazione Italiana Radioterapia Oncologica. Prac-
tice guidelines issued by Associazione Italiana Radioterapia
Oncologica (AIRO) group recommended endoscopic exam
every 1-2 months for year 1, every 2-3 months for year 2,
every 4–6 months for years 3–5, and then annually. Based on
primary tumor localization, MRI or CT is indicated every 6
months for 2 years (for 4 years in nasopharynx) and then if
there are symptoms. In the case of an uncertain diagnosis, a
PET/TC exam [20] is recommended.
3.4. British Association of Head and Neck Oncologists. The
British Association of Head andNeck Oncologists (BAHNO)
scheduled follow-up visits every 4–6 weeks during the first
and the second year after therapy, every 3 months for year
3, every 6 months for years 4-5, and then annually. Imaging
baseline study is recommended 3 months after completion of
treatment [21].
4. General Clinical and Imaging Evaluation
Posttreatment evaluation, both clinical and radiologic, is
necessary to detect tissue modifications. During follow-
up examinations the major difficulty is distinguishing local
recurrence from treatment toxicity, as a result of surgery or
radiation-induced tissue distortions.
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4.1. Clinical Exam. Local control clinical assessment is an
inexpensive method to follow up patients after treatment. It
is paramount after completing treatment, even if it should
be difficult due to treatment effects on mucosa. Because
of anatomic changes, such as fibrosis and lymph edema,
the efficacy of clinical examination, especially in palpation,
could make detection of recurrence difficult. On the other
hand, these changes, as well as those secondary to flap
reconstruction and vascularized scar, could determine high
false-positive rates at imaging [22]. Hypothetically a mucosal
recurrence may be missed on follow-up routine imaging-
based information. Therefore a scrupulous complete H&N
clinical examination, with mirror examination and fiberoptic
nasopharyngoscopy, must be performed.
4.2. Imaging Evaluation. Cross-sectional imaging exams are
fundamental to evaluate H&N district. Computed tomogra-
phy (CT) scan, magnetic resonance (MR) imaging, and 18-
F-fluorodeoxyglucose positron emission tomography (18-F-
FDG-PET) are nowadays considered standard for estimating
treatment response in H&N cancer. Which is the modality to
choose depends on clinical practice. Generally, the posttreat-
ment baseline imaging exam should be the same that has been
used in the pretreatment evaluation [23].
Historically, CT is used to assess posttreatment response
in H&N cancer. Obviously a CT scan performed without
contrast is not optimal for H&N district, because tumor and
lymphoid tissue, as well asmuscle, have the same density [24].
MR has the advantage over CT to provide a better
soft-tissue differentiation. It is recommended in case of
nasopharyngeal, base of tongue, sinonasal, or skull base car-
cinomas [25]. Due to the limited accuracy of bothmodalities,
especially in lymph node evaluation, new functional imaging
technologies are being employed. Diffusion weighted imag-
ing (DWI) is an MR technique that has been suggested as
noninvasive imaging biomarker to predict tumor response.
The obvious advantage of DWI-MR, which uses water
molecules motion in intracellular and extracellular space to
reflect biological changes in tumour microenvironment, is
that it is useful for accurately distinguishing recurrent disease
from radiation-induced soft-tissue changes [5, 26]. DWI-MR
should detect the disease before the patient notices a return
of any symptom.
The diagnostic accuracy of 18-F-FDG-PET after surgery
or (chemo)radiotherapy has been tested in recurrence deten-
tion of H&N cancer. Independently of treatment modality,
literature data indicated a better accuracy with 18-F-FDG-
PET than with CT and/or MRI (𝑃 = 0.03) [27]. However,
the role of 18-F-FDG-PET has been especially investigated
in the postradiotherapy surveillance and thus its known
accuracy limitations due to treatment induced inflammation
[28]. Following definitive (chemo)radiotherapy, a residual CT
abnormality in the neck, but a negative PET scan, defined
as the absence of metabolic activity, is associated with no
nodal progression [29]. FDG-PET should also be helpful
in the distinction of tissue necrosis from recurrent tumor
[30]. Considering that 18-F-FDG uptake may be observed
in normal tissues, such as lymphoid tissue, vocal cord, and
cervical muscles, a potential role of other PET radiotracers
has been tested. 18-F-Fluorothymidine for DNA synthesis
(18-F-FLT) seems to be the most promising due to its high
specificity; however its real utility is currently not firmly
demonstrated [31]. Therefore PET with the tracer 18-F-FDG
is still the standard. To reduce false-positive results, 18-F-
FDG-PET should be performed at 10–12 weeks after the end
of treatment; this time point is also considered an optimal
balance between clinical response evaluation and surgical
management, if necessary [29].
5. Point of View
There are important differences among the guidelines regard-
ing frequency of routine visits and evidence-based data on
timing surveillance are lacking.Thedecision of posttreatment
surveillance seems a matter of geography. A randomized trial
comparing a specific follow-up strategy with a self-patient
referral policy is not yet available.
Many physicians continue to order imaging studies in
asymptomatic patients based on believing that earlier detec-
tion of relapse will favourably influence the final outcome.
The potential benefits of a shorter surveillance than recom-
mended intervals need to be weighed against the potential
exposition of patients to unnecessary risks and cost. Certainly
routine follow-up is the better chance of managing treatment
toxicities and providing reassurance.
6. Conclusion
We can conclude that unanimous consensus on optimum
posttreatment follow-up in patients with H&N cancer does
not exist. The aim is to adopt a rational follow-up program
that reassures patients, minimizes patients discomfort, saves
time, and reduces costs. All patients should have routinely
nasopharyngoscopy and posttreatment baseline imaging.
Imaging with CT or MRI or PET at regular intervals had no
advantage over improvement of patients’ outcomes.
Prospective studies are needed. The goal would be to
avoid being overly aggressive in clear situationwhile ensuring
sufficiently determination in dubious condition.
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